Biotech Values

[DewDiligence]

ABBV/ENTA’s G/P HCV regimen receives priority review in Japan:

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2253727

G/P already has FDA priority review (#msg-128359345) and EMA accelerated assessment (#msg-128090944).

The FDA PDUFA date is on or about 8/2/17, and G/P will likely be on the market in all three jurisdictions (US, EU, and Japan) by the end of 2017.

ENTA will receive a cumulative $80M in milestone payments from ABBV for G/P approval in these three jurisdictions.

ENTA will receive tiered royalties on worldwide sales of G/P—see #msg-126723412.

Please see #msg-126481635, #msg-126481950, #msg-127727429, and #msg-122031014 for G/P clinical data and phase-3 program.